Obesity最新文献

英文中文

Combined diet and exercise training decreases serum lipids associated with insulin resistance 结合饮食和运动训练可降低与胰岛素抵抗有关的血清脂质。

IF 4.2 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Obesity

Pub Date : 2024-11-26 DOI: 10.1002/oby.24156

Josiane L. Broussard, Amanda Garfield, Simona Zarini, Joseph T. Brozinick, Leigh Perreault, Sean A. Newsom, Darcy Kahn, Anna Kerege, Karin Zemski Berry, Hai Hoang Bui, Bryan C. Bergman

Objective

Circulating lipids are linked with insulin resistance and increased cardiovascular disease risk. We previously reported that dihydroceramides, a specific type of sphingolipid, are elevated in insulin-resistant individuals; however, little is known regarding whether insulin-sensitizing lifestyle interventions can improve profiles of sphingolipids and other lipid species.

Methods

A total of 21 individuals with obesity participated in a 3-month lifestyle intervention of combined weight loss and exercise training. Insulin sensitivity was assessed by hyperinsulinemic-euglycemic clamps, and serum lipidomics was conducted.

Results

Following the intervention, BMI was significantly reduced by 10%; VO₂peak and insulin sensitivity increased by 12% and 57%, respectively; and total serum triacylglycerol (TAG), diacylglycerol, dihydroceramides, sphingosine-1-phosphate, and sphinganine-1-phosphate were significantly reduced, as were specific species of dihydroceramides (C18:0 and C24:1). Individuals with higher preintervention TAG concentrations had significant decreases in serum lipids, which were not significantly changed in individuals with lower preintervention TAG.

Conclusions

These data show that serum sphingolipid species previously linked to insulin resistance in humans can be reduced with insulin-sensitizing lifestyle interventions. Furthermore, individuals with elevated serum TAG may significantly benefit from lifestyle interventions that increase insulin sensitivity due to a greater decrease in serum lipids related to insulin resistance.

目的：循环血脂与胰岛素抵抗和心血管疾病风险增加有关。我们以前曾报道过，胰岛素抵抗的人体内二氢甘油三酯（一种特殊的鞘脂类）会升高；然而，对于胰岛素敏感的生活方式干预是否能改善鞘脂类和其他脂类的特征，我们所知甚少：方法：共有 21 名肥胖症患者参加了为期 3 个月的生活方式干预，其中包括减肥和运动训练。通过高胰岛素血糖钳夹评估胰岛素敏感性，并进行血清脂质组学研究：结果：干预后，体重指数明显降低了 10%；VO2 峰值和胰岛素敏感性分别提高了 12% 和 57%；血清总三酰甘油 (TAG)、二酰甘油、二氢甘油酰胺、鞘氨醇-1-磷酸酯和鞘氨醇-1-磷酸酯以及特定种类的二氢甘油酰胺（C18:0 和 C24:1）均明显减少。干预前 TAG 浓度较高的人血清脂质明显减少，而干预前 TAG 浓度较低的人血清脂质没有明显变化：这些数据表明，以前与人类胰岛素抵抗有关的血清鞘脂种类可以通过胰岛素敏感的生活方式干预来减少。此外，由于与胰岛素抵抗有关的血清脂类会进一步减少，血清 TAG 升高的人可能会从提高胰岛素敏感性的生活方式干预中明显受益。

{"title":"Combined diet and exercise training decreases serum lipids associated with insulin resistance","authors":"Josiane L. Broussard, Amanda Garfield, Simona Zarini, Joseph T. Brozinick, Leigh Perreault, Sean A. Newsom, Darcy Kahn, Anna Kerege, Karin Zemski Berry, Hai Hoang Bui, Bryan C. Bergman","doi":"10.1002/oby.24156","DOIUrl":"10.1002/oby.24156","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Circulating lipids are linked with insulin resistance and increased cardiovascular disease risk. We previously reported that dihydroceramides, a specific type of sphingolipid, are elevated in insulin-resistant individuals; however, little is known regarding whether insulin-sensitizing lifestyle interventions can improve profiles of sphingolipids and other lipid species.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 21 individuals with obesity participated in a 3-month lifestyle intervention of combined weight loss and exercise training. Insulin sensitivity was assessed by hyperinsulinemic-euglycemic clamps, and serum lipidomics was conducted.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Following the intervention, BMI was significantly reduced by 10%; VO<sub>2</sub>peak and insulin sensitivity increased by 12% and 57%, respectively; and total serum triacylglycerol (TAG), diacylglycerol, dihydroceramides, sphingosine-1-phosphate, and sphinganine-1-phosphate were significantly reduced, as were specific species of dihydroceramides (C18:0 and C24:1). Individuals with higher preintervention TAG concentrations had significant decreases in serum lipids, which were not significantly changed in individuals with lower preintervention TAG.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These data show that serum sphingolipid species previously linked to insulin resistance in humans can be reduced with insulin-sensitizing lifestyle interventions. Furthermore, individuals with elevated serum TAG may significantly benefit from lifestyle interventions that increase insulin sensitivity due to a greater decrease in serum lipids related to insulin resistance.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"32 12","pages":"2334-2344"},"PeriodicalIF":4.2,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142718089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Poster Abstracts 海报摘要

IF 4.2 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Obesity

Pub Date : 2024-11-19 DOI: 10.1002/oby.24195

引用次数: 0

Oral Abstracts 口头摘要

IF 4.2 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Obesity

Pub Date : 2024-11-19 DOI: 10.1002/oby.24194

引用次数: 0

Weight maintenance on cost-effective antiobesity medications after 1 year of GLP-1 receptor agonist therapy: a real-world study GLP-1 受体激动剂治疗 1 年后使用经济有效的抗肥胖药物维持体重：一项真实世界研究。

IF 4.2 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Obesity

Pub Date : 2024-11-18 DOI: 10.1002/oby.24177

Nina U. Paddu, Brianna Lawrence, Sydnee Wong, Sabrina J. Poon, Gitanjali Srivastava

Objective

The high cost of novel glucagon-like peptide-1 receptor agonist (GLP-1 RA) class agents often limits access and creates barriers to care. This real-world study evaluated the efficacy of older-generation generic antiobesity medications (AOMs) for weight maintenance after 1 year of GLP-1 RA therapy in patients who had achieved successful weight loss.

Methods

We prospectively followed patients (N = 105) who had completed 12 months of therapy and were part of a “medical weight loss bundle,” which included 12 months of GLP-1 RA therapy followed by 6 months of transition care. The baseline mean BMI was 36.4 kg/m². Body weight outcomes were measured at 6, 12, 18, and 24 months.

Results

After the medical weight loss bundle, 40 patients transitioned to generic AOMs. At 12 months, this cohort lost an average of 18.3%, 95% CI [13.0%, 23.6%] body weight from baseline, with a mean BMI of 27.9 kg/m². At 18 months, they maintained the weight loss, with a mean BMI of 27.9 kg/m². Subsequent follow-up visits (average 1.5 months later) without GLP-1 RAs showed further reduction, resulting in a total average weight loss of 25.5%, 95% CI [23.1%, 27.9%] compared to the initial visit.

Conclusions

Patients successfully treated with GLP-1 RAs can maintain their weight loss using generic older-generation AOMs, suggesting potential cost savings for insurers and implications for policy regarding AOM coverage.

目的：新型胰高血糖素样肽-1受体激动剂（GLP-1 RA）类药物的高昂价格往往限制了患者的使用，并给治疗带来了障碍。这项真实世界研究评估了已成功减轻体重的患者在接受 GLP-1 RA 治疗一年后使用老一代普通抗肥胖药物（AOMs）维持体重的疗效：我们对已完成 12 个月治疗的患者（N = 105）进行了前瞻性随访，这些患者属于 "医疗减重捆绑 "的一部分，其中包括 12 个月的 GLP-1 RA 治疗和 6 个月的过渡护理。基线平均体重指数为 36.4 kg/m2。体重结果在 6、12、18 和 24 个月时进行测量：结果：在接受医疗减重捆绑治疗后，40 名患者转为接受普通 AOMs 治疗。12 个月时，这些患者的体重与基线相比平均下降了 18.3%，95% CI [13.0%, 23.6%]，平均体重指数（BMI）为 27.9 kg/m2。18 个月后，他们的体重保持不变，平均体重指数为 27.9 kg/m2。随后的随访（平均 1.5 个月后）显示，未使用 GLP-1 RAs 的患者体重进一步下降，与首次随访相比，总平均体重下降了 25.5%，95% CI [23.1%, 27.9%]：结论：使用GLP-1 RAs治疗成功的患者可以使用普通的老一代AOMs维持体重减轻，这表明保险公司有可能节约成本，并对AOM的覆盖政策产生影响。

{"title":"Weight maintenance on cost-effective antiobesity medications after 1 year of GLP-1 receptor agonist therapy: a real-world study","authors":"Nina U. Paddu, Brianna Lawrence, Sydnee Wong, Sabrina J. Poon, Gitanjali Srivastava","doi":"10.1002/oby.24177","DOIUrl":"10.1002/oby.24177","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The high cost of novel glucagon-like peptide-1 receptor agonist (GLP-1 RA) class agents often limits access and creates barriers to care. This real-world study evaluated the efficacy of older-generation generic antiobesity medications (AOMs) for weight maintenance after 1 year of GLP-1 RA therapy in patients who had achieved successful weight loss.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We prospectively followed patients (<i>N</i> = 105) who had completed 12 months of therapy and were part of a “medical weight loss bundle,” which included 12 months of GLP-1 RA therapy followed by 6 months of transition care. The baseline mean BMI was 36.4 kg/m<sup>2</sup>. Body weight outcomes were measured at 6, 12, 18, and 24 months.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>After the medical weight loss bundle, 40 patients transitioned to generic AOMs. At 12 months, this cohort lost an average of 18.3%, 95% CI [13.0%, 23.6%] body weight from baseline, with a mean BMI of 27.9 kg/m<sup>2</sup>. At 18 months, they maintained the weight loss, with a mean BMI of 27.9 kg/m<sup>2</sup>. Subsequent follow-up visits (average 1.5 months later) without GLP-1 RAs showed further reduction, resulting in a total average weight loss of 25.5%, 95% CI [23.1%, 27.9%] compared to the initial visit.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Patients successfully treated with GLP-1 RAs can maintain their weight loss using generic older-generation AOMs, suggesting potential cost savings for insurers and implications for policy regarding AOM coverage.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"32 12","pages":"2255-2263"},"PeriodicalIF":4.2,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.24177","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142668949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sex differences in ectopic lipid deposits and cardiac function across a wide range of glycemic control: a secondary analysis 不同血糖控制范围内异位脂质沉积和心脏功能的性别差异：二次分析。

IF 4.2 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Obesity

Pub Date : 2024-11-18 DOI: 10.1002/oby.24153

Jürgen Harreiter, Ivica Just, Michael Weber, Radka Klepochová, Magdalena Bastian, Yvonne Winhofer, Peter Wolf, Thomas Scherer, Michael Leutner, Lana Kosi-Trebotic, Carola Deischinger, Marek Chmelík, Michael R. Krebs, Siegfried Trattnig, Martin Krššák, Alexandra Kautzky-Willer

Objective

The objective of this study was to identify sex differences in ntrahepatocellular (HCL) and intramyocardial lipids (MYCL) and cardiac function in participants with different grades of glucometabolic impairment and different BMI strata.

Methods

Data from 503 individuals from 17 clinical experimental studies were analyzed. HCL and MYCL were assessed with 3T and 7T scanners by magnetic resonance spectroscopy. Cardiac function was measured with a 3T scanner using electrocardiogram-gated TrueFISP sequences. Participants were classified as having normoglycemia, prediabetes, or type 2 diabetes. Three-way ANCOVA with post hoc simple effects analyses was used for statistical assessment.

Results

Consistent increases of HCL with BMI and deterioration of glucose metabolism, especially in female individuals, were detected. MYCL increased with BMI and glucose impairment in female individuals, but not in male individuals. Sex differences were found in cardiac function loss, with significant effects found among male individuals with worsening glucose metabolism. Myocardial mass and volume of the ventricle were higher in male individuals in all groups. This sex difference narrowed with increasing BMI and with progressing dysglycemia.

Conclusions

Sex differences in HCL and MYCL may be associated with a higher cardiovascular disease risk observed in female individuals progressing to diabetes. Further studies are needed to elucidate possible sex differences with advancing glucometabolic impairment and obesity and their potential impact on cardiovascular outcomes.

研究目的本研究的目的是确定不同糖代谢损害等级和不同体重指数阶层的参与者在肝细胞内脂质（HCL）和心肌内脂质（MYCL）以及心脏功能方面的性别差异：分析了 17 项临床实验研究中 503 人的数据。使用 3T 和 7T 扫描仪通过磁共振波谱对 HCL 和 MYCL 进行评估。使用心电图门控 TrueFISP 序列在 3T 扫描仪上测量心脏功能。参与者被分为正常血糖、糖尿病前期或 2 型糖尿病。统计评估采用三方方差分析和事后简单效应分析：结果：发现 HCL 随体重指数（BMI）和糖代谢恶化（尤其是女性）而持续增加。MYCL随女性体重指数和糖代谢障碍的增加而增加，但男性则没有。在心功能减退方面发现了性别差异，在糖代谢恶化的男性个体中发现了显著的影响。在所有组别中，男性的心肌质量和心室容积都更高。这种性别差异随着体重指数（BMI）的增加和血糖异常的恶化而缩小：结论：HCL 和 MYCL 的性别差异可能与女性糖尿病患者心血管疾病风险较高有关。还需要进一步的研究来阐明随着糖代谢障碍和肥胖的进展可能出现的性别差异及其对心血管疾病的潜在影响。

{"title":"Sex differences in ectopic lipid deposits and cardiac function across a wide range of glycemic control: a secondary analysis","authors":"Jürgen Harreiter, Ivica Just, Michael Weber, Radka Klepochová, Magdalena Bastian, Yvonne Winhofer, Peter Wolf, Thomas Scherer, Michael Leutner, Lana Kosi-Trebotic, Carola Deischinger, Marek Chmelík, Michael R. Krebs, Siegfried Trattnig, Martin Krššák, Alexandra Kautzky-Willer","doi":"10.1002/oby.24153","DOIUrl":"10.1002/oby.24153","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The objective of this study was to identify sex differences in ntrahepatocellular (HCL) and intramyocardial lipids (MYCL) and cardiac function in participants with different grades of glucometabolic impairment and different BMI strata.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data from 503 individuals from 17 clinical experimental studies were analyzed. HCL and MYCL were assessed with 3T and 7T scanners by magnetic resonance spectroscopy. Cardiac function was measured with a 3T scanner using electrocardiogram-gated TrueFISP sequences. Participants were classified as having normoglycemia, prediabetes, or type 2 diabetes. Three-way ANCOVA with post hoc simple effects analyses was used for statistical assessment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Consistent increases of HCL with BMI and deterioration of glucose metabolism, especially in female individuals, were detected. MYCL increased with BMI and glucose impairment in female individuals, but not in male individuals. Sex differences were found in cardiac function loss, with significant effects found among male individuals with worsening glucose metabolism. Myocardial mass and volume of the ventricle were higher in male individuals in all groups. This sex difference narrowed with increasing BMI and with progressing dysglycemia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Sex differences in HCL and MYCL may be associated with a higher cardiovascular disease risk observed in female individuals progressing to diabetes. Further studies are needed to elucidate possible sex differences with advancing glucometabolic impairment and obesity and their potential impact on cardiovascular outcomes.</p>\u0000 \u0000 <div>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"32 12","pages":"2299-2309"},"PeriodicalIF":4.2,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.24153","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142668943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Attenuation of high-fat diet-induced weight gain by apolipoprotein A4 载脂蛋白 A4 可减轻高脂饮食引起的体重增加。

IF 4.2 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Obesity

Pub Date : 2024-11-14 DOI: 10.1002/oby.24155

Hsuan-Chih N. Kuo, Zachary LaRussa, Flora Mengyang Xu, Leslie A. Consitt, Min Liu, W. Sean Davidson, Vishwajeet Puri, Karen T. Coschigano, Haifei Shi, Chunmin C. Lo

Objective

Apolipoprotein A4 (APOA4) is synthesized by the small intestine in response to dietary lipids. Chronic exposure to a high-fat diet (HFD) desensitizes lipid-induced APOA4 production and attenuates brown adipose tissue (BAT) thermogenesis. We hypothesized that exogenous APOA4 could increase BAT thermogenesis and energy expenditure in HFD-fed mice, resulting in decreased obesity and improved glucose tolerance.

Methods

BAT and inguinal white adipose tissue (IWAT) thermogenesis, body composition, energy intake and expenditure, and locomotor activity were measured using an infrared camera, immunoblots, quantitative magnetic resonance imaging, and a comprehensive lab animal monitoring system. An intraperitoneal glucose tolerance test and hepatic lipid accumulation and steatosis were assayed.

Results

Mice receiving continuous infusion of APOA4 for the last 4 weeks of 10 weeks of HFD feeding gained no additional body weight and had reduced fat mass but enhanced BAT and IWAT thermogenesis and energy expenditure, despite unaltered food intake and locomotor activity. Additionally, APOA4 infusion elevated fatty acid β oxidation; decreased lipogenesis, lipid accumulation, and steatosis in liver; and improved glucose tolerance.

Conclusions

Maintenance of plasma APOA4 via exogenous APOA4 protein parallels elevation of BAT and IWAT thermogenesis, hepatic fatty acid β oxidation, and overall energy expenditure, with subsequent prevention of additional weight gain in HFD-fed obese mice.

目的：载脂蛋白 A4（APOA4）是由小肠对膳食脂质做出反应而合成的。长期暴露于高脂饮食（HFD）会使脂质诱导的 APOA4 生成脱敏，并削弱棕色脂肪组织（BAT）的产热。我们假设外源性 APOA4 可增加高脂饮食小鼠 BAT 的产热和能量消耗，从而减少肥胖并改善葡萄糖耐量：方法：使用红外摄像机、免疫印迹、定量磁共振成像和综合实验动物监测系统测量了BAT和腹股沟白色脂肪组织（IWAT）的产热、身体成分、能量摄入和消耗以及运动活动。此外，还进行了腹腔葡萄糖耐量试验以及肝脏脂质积累和脂肪变性检测：结果：在喂食高纤维食物 10 周的最后 4 周，小鼠持续输注 APOA4，体重没有增加，脂肪量减少，但 BAT 和 IWAT 产热和能量消耗增加，尽管食物摄入量和运动活动没有改变。此外，APOA4输注可提高脂肪酸β氧化；减少脂肪生成、脂质积累和肝脏脂肪变性；改善葡萄糖耐量：结论：通过外源性 APOA4 蛋白维持血浆 APOA4 可提高 BAT 和 IWAT 产热、肝脏脂肪酸 β 氧化和总体能量消耗，从而防止高密度脂蛋白喂养肥胖小鼠体重增加。

{"title":"Attenuation of high-fat diet-induced weight gain by apolipoprotein A4","authors":"Hsuan-Chih N. Kuo, Zachary LaRussa, Flora Mengyang Xu, Leslie A. Consitt, Min Liu, W. Sean Davidson, Vishwajeet Puri, Karen T. Coschigano, Haifei Shi, Chunmin C. Lo","doi":"10.1002/oby.24155","DOIUrl":"10.1002/oby.24155","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Apolipoprotein A4 (APOA4) is synthesized by the small intestine in response to dietary lipids. Chronic exposure to a high-fat diet (HFD) desensitizes lipid-induced APOA4 production and attenuates brown adipose tissue (BAT) thermogenesis. We hypothesized that exogenous APOA4 could increase BAT thermogenesis and energy expenditure in HFD-fed mice, resulting in decreased obesity and improved glucose tolerance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>BAT and inguinal white adipose tissue (IWAT) thermogenesis, body composition, energy intake and expenditure, and locomotor activity were measured using an infrared camera, immunoblots, quantitative magnetic resonance imaging, and a comprehensive lab animal monitoring system. An intraperitoneal glucose tolerance test and hepatic lipid accumulation and steatosis were assayed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Mice receiving continuous infusion of APOA4 for the last 4 weeks of 10 weeks of HFD feeding gained no additional body weight and had reduced fat mass but enhanced BAT and IWAT thermogenesis and energy expenditure, despite unaltered food intake and locomotor activity. Additionally, APOA4 infusion elevated fatty acid β oxidation; decreased lipogenesis, lipid accumulation, and steatosis in liver; and improved glucose tolerance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Maintenance of plasma APOA4 via exogenous APOA4 protein parallels elevation of BAT and IWAT thermogenesis, hepatic fatty acid β oxidation, and overall energy expenditure, with subsequent prevention of additional weight gain in HFD-fed obese mice.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"32 12","pages":"2321-2333"},"PeriodicalIF":4.2,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.24155","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The moderating effect of cardiometabolic factors on the association between hepatic and intrapancreatic fat 心脏代谢因素对肝脏脂肪和胰内脂肪之间关系的调节作用。

IF 4.2 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Obesity

Pub Date : 2024-11-10 DOI: 10.1002/oby.24154

Loren Skudder-Hill, Ivana R. Sequeira-Bisson, Juyeon Ko, Sally D. Poppitt, Maxim S. Petrov

Objective

Previous studies have investigated the association between hepatic fat and intrapancreatic fat deposition (IPFD); however, results have been inconclusive. The presence of cardiometabolic factors in certain subpopulations could explain this discrepancy. The aim of the present study was to use moderation analyses to determine the conditions under which hepatic fat is associated with IPFD.

Methods

All participants underwent 3T abdominal magnetic resonance imaging (MRI) and spectroscopy. Hepatic fat and IPFD were manually quantified by independent raters. Moderation analyses were performed with adjustment for sex and ethnicity.

Results

There were 367 participants included. Adjusted analyses of the overall cohort revealed that age, glycated hemoglobin (HbA_1c), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides were significant moderators (p < 0.05) of the association between hepatic fat and IPFD. Ranges of significance included age < 61 years, HbA_1c < 45 mmol/mol, LDL-C < 157 mg/dL, HDL-C > 36 mg/dL, and triglycerides < 203 mg/dL.

Conclusions

The association between hepatic fat and IPFD is generally present in young and middle-aged adults with good cardiometabolic health, whereas the link between the two fat depots becomes uncoupled in older adults or individuals with cardiometabolic risk factors.

研究目的以往的研究对肝脏脂肪与胰腺内脂肪沉积（IPFD）之间的关系进行了调查，但结果并不一致。某些亚人群中存在的心脏代谢因素可以解释这种差异。本研究旨在使用调节分析法确定肝脏脂肪与胰腺脂肪沉积相关的条件：所有参与者都接受了 3T 腹部磁共振成像（MRI）和光谱分析。肝脏脂肪和 IPFD 由独立评分员手动量化。结果：共纳入 367 名参与者：结果：共纳入 367 名参与者。对总体队列的调整分析表明，年龄、糖化血红蛋白（HbA1c）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）和甘油三酯是显著的调节因子（p 1c 36 mg/dL，甘油三酯结论：肝脏脂肪和 IPFD 之间的关系是由肝脏脂肪和 IPFD 之间的关系决定的：肝脏脂肪和 IPFD 之间的联系一般存在于心脏代谢健康状况良好的中青年人中，而这两个脂肪库之间的联系在老年人或存在心脏代谢风险因素的个体中变得不相关。

{"title":"The moderating effect of cardiometabolic factors on the association between hepatic and intrapancreatic fat","authors":"Loren Skudder-Hill, Ivana R. Sequeira-Bisson, Juyeon Ko, Sally D. Poppitt, Maxim S. Petrov","doi":"10.1002/oby.24154","DOIUrl":"10.1002/oby.24154","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Previous studies have investigated the association between hepatic fat and intrapancreatic fat deposition (IPFD); however, results have been inconclusive. The presence of cardiometabolic factors in certain subpopulations could explain this discrepancy. The aim of the present study was to use moderation analyses to determine the conditions under which hepatic fat is associated with IPFD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>All participants underwent 3T abdominal magnetic resonance imaging (MRI) and spectroscopy. Hepatic fat and IPFD were manually quantified by independent raters. Moderation analyses were performed with adjustment for sex and ethnicity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>There were 367 participants included. Adjusted analyses of the overall cohort revealed that age, glycated hemoglobin (HbA<sub>1c</sub>), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides were significant moderators (<i>p</i> < 0.05) of the association between hepatic fat and IPFD. Ranges of significance included age < 61 years, HbA<sub>1c</sub> < 45 mmol/mol, LDL-C < 157 mg/dL, HDL-C > 36 mg/dL, and triglycerides < 203 mg/dL.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The association between hepatic fat and IPFD is generally present in young and middle-aged adults with good cardiometabolic health, whereas the link between the two fat depots becomes uncoupled in older adults or individuals with cardiometabolic risk factors.</p>\u0000 \u0000 <div>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"32 12","pages":"2310-2320"},"PeriodicalIF":4.2,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.24154","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to “Obesity increases the risk of hepatic fibrosis in young adults with type 2 diabetes mellitus: The need to screen” 更正 "肥胖会增加 2 型糖尿病青壮年患者肝纤维化的风险：需要进行筛查"。

IF 4.2 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Obesity

Pub Date : 2024-11-07 DOI: 10.1002/oby.24179

Sharma, A, Leiva, EG, Kalavalapalli, S, et al. Obesity increases the risk of hepatic fibrosis in young adults with type 2 diabetes mellitus: the need to screen. Obesity. 2024; 10: 1967–1974.

On page 1967, the author name Eddison Godina Leiva was incorrect. It should be corrected to Eddison Godinez Leiva.

The online version of the article has been corrected accordingly.

We apologize for this error.

Sharma，A，Leiva，EG，Kalavalapalli，S，et al.肥胖会增加 2 型糖尿病青壮年肝纤维化的风险：需要筛查。肥胖症 2024；10：1967-1974.第 1967 页，作者姓名 Eddison Godina Leiva 有误。在线版本的文章已作相应更正。我们对此错误深表歉意。

引用次数: 0

Early changes in the gut microbiota are associated with weight outcomes over 2 years following metabolic and bariatric surgery 肠道微生物群的早期变化与代谢和减肥手术后两年内的体重结果有关。

IF 4.2 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Obesity

Pub Date : 2024-11-05 DOI: 10.1002/oby.24168

Kristine J. Steffen, Alicia A. Sorgen, Anthony A. Fodor, Ian M. Carroll, Ross D. Crosby, James E. Mitchell, Dale S. Bond, Leslie J. Heinberg

Objective

Metabolic and bariatric surgery (MBS) is associated with substantial, but variable, weight outcomes. The gut microbiome may be a factor in determining weight trajectory, but examination has been limited by a lack of longitudinal studies with robust microbiome sequencing. This study aimed to describe changes in the microbiome and associations with weight outcomes more than 2 years post surgery.

Methods

Data were collected at two Midwestern U.S. centers. Adults undergoing primary MBS were assessed before and 1, 6, 12, 18, and 24 months after surgery. BMI and metagenomic sequencing occurred at each assessment. A linear growth mixture model determined class structure for weight trajectory.

Results

A linear growth mixture model of participants (N = 124) revealed a two-class structure; one class had greater sustained weight loss relative to the other. Greater genus-level taxonomic changes in the microbiome composition at each time point were associated with being in the more favorable weight trajectory class, after controlling for surgery type. Higher Proteobacteria relative abundance at 1 month was predictive of percentage weight change at 6, 12, 18, and 24 months (p < 0.05 for all).

Conclusions

Greater genus-level taxonomic changes in the gut microbiota are associated with improved weight trajectory. Early changes in the gut microbiota may be an important indicator of MBS outcomes and durability.

目的：代谢和减肥手术（MBS）与大量但多变的体重结果有关。肠道微生物组可能是决定体重轨迹的一个因素，但由于缺乏对微生物组进行可靠测序的纵向研究，对其进行的研究受到了限制。本研究旨在描述微生物组的变化以及与术后两年以上体重结果的关联：方法：在美国中西部的两个中心收集数据：方法：在美国中西部的两个中心收集数据：对接受初级 MBS 的成人进行术前和术后 1、6、12、18 和 24 个月的评估。每次评估都进行体重指数和元基因组测序。线性生长混合模型确定了体重轨迹的等级结构：结果：参与者（N = 124）的线性生长混合模型显示出两类结构；一类相对于另一类有更大的持续体重减轻。在控制手术类型后，每个时间点微生物组组成中更大的属级分类变化与体重轨迹更有利的类别相关。1个月时较高的蛋白质细菌相对丰度可预测6、12、18和24个月时的体重变化百分比（p 结论：1个月时较高的蛋白质细菌相对丰度可预测6、12、18和24个月时的体重变化百分比：肠道微生物群中更大的属级分类变化与体重轨迹的改善有关。肠道微生物群的早期变化可能是衡量 MBS 效果和持久性的重要指标。

{"title":"Early changes in the gut microbiota are associated with weight outcomes over 2 years following metabolic and bariatric surgery","authors":"Kristine J. Steffen, Alicia A. Sorgen, Anthony A. Fodor, Ian M. Carroll, Ross D. Crosby, James E. Mitchell, Dale S. Bond, Leslie J. Heinberg","doi":"10.1002/oby.24168","DOIUrl":"10.1002/oby.24168","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Metabolic and bariatric surgery (MBS) is associated with substantial, but variable, weight outcomes. The gut microbiome may be a factor in determining weight trajectory, but examination has been limited by a lack of longitudinal studies with robust microbiome sequencing. This study aimed to describe changes in the microbiome and associations with weight outcomes more than 2 years post surgery.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data were collected at two Midwestern U.S. centers. Adults undergoing primary MBS were assessed before and 1, 6, 12, 18, and 24 months after surgery. BMI and metagenomic sequencing occurred at each assessment. A linear growth mixture model determined class structure for weight trajectory.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A linear growth mixture model of participants (<i>N</i> = 124) revealed a two-class structure; one class had greater sustained weight loss relative to the other. Greater genus-level taxonomic changes in the microbiome composition at each time point were associated with being in the more favorable weight trajectory class, after controlling for surgery type. Higher Proteobacteria relative abundance at 1 month was predictive of percentage weight change at 6, 12, 18, and 24 months (<i>p</i> < 0.05 for all).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Greater genus-level taxonomic changes in the gut microbiota are associated with improved weight trajectory. Early changes in the gut microbiota may be an important indicator of MBS outcomes and durability.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"32 11","pages":"1985-1997"},"PeriodicalIF":4.2,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.24168","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142577322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to Dodd et al.: contextualizing pregnancy weight research within clinical and public health practice 对 Dodd 等人的回应：在临床和公共卫生实践中开展孕期体重研究。

IF 4.2 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Obesity

Pub Date : 2024-11-05 DOI: 10.1002/oby.24170

Janne Boone-Heinonen, Jonathan M. Snowden, Kimberly K. Vesco, Erin S. LeBlanc, Teresa Schmidt, Rachel Springer

引用次数: 0

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Obesity

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀